Inna Vainshtein

Inna Vainshtein is an accomplished bioanalytical scientist currently serving as Executive Director of Bioanalysis at Exelixis since July 2020, after progressing from Senior Director, where leadership encompasses bioanalytical support for various therapeutic modalities. Prior experience includes significant roles at AstraZeneca/MedImmune, contributing to the development of PK/PD/ADA/biomarker and imaging assays for biologics from October 2006 to July 2020, and earlier positions at Geron Corp., Abgenix, DiscoveRx, Stanford University, and the University of Alberta. Inna Vainshtein holds a Ph.D. in Molecular Biology from the All-Union Research Institute for Genetics and Selection of Industrial Microorganisms in Moscow, Russia, earned between 1985 and 1991.